Upadacitinib for Prurigo Nodularis

Part of paid clinical trials in East Windsor, New Jersey.

Sponsor
Psoriasis Treatment Center of Central New Jersey
Study ID
NCT06773403
Phase
PHASE4
Status
Terminated

Conditions

  • Prurigo Nodularis

Eligibility Criteria

Sex
ALL
Age
18 Years - 64 Years
Healthy Volunteers
Not accepted

Interventions

  • Upadacitinib — DRUG
    All subject start on 15mg. At week 8 subjects may increase to 30mg if the investigators deems it necessary.

Study Details

A single center, open-label study of 25 subjects to assess 24 weeks upadacitinib in patients with moderate-to-severe prurigo nodularis.

Key Dates

Start date
Apr 9, 2024
Status verified
May 2026
Primary completion
Jun 6, 2025
Completion
Jun 6, 2025

Study Design

Enrollment
5 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Other: Upadacitinib
    Open-label use of 15mg upadacitinib. Subjects have the option to increase to 30mg at week 8 if the investigator deems it necessary.

Primary Outcome Measure

Reduction in worst-itch numeric rating scale (WI-NRS) at week 12 [ Time Frame: 12 weeks ]

Locations (1)

FacilityCityStateZIPSite coordinators
Eczema Treatment Center of New JerseyEast WindsorNew Jersey08520-

Find similar trials in East Windsor, NJ

By research site
Eczema Treatment Center of New Jersey· East Windsor, NJ

Related Studies